Palette Life Sciences has signed an agreement to provide additional marketing in the U.S. for Lantheus Medical Imaging's Pylarify (piflufolastat F-18) PET radiotracer.
Under the one-year, nonexclusive deal, Palette's urology and oncology sales team will assist in promotional efforts aimed at educating healthcare professionals on the benefits and availability of Pylarify, a PET radiopharmaceutical designed to target prostate-specific membrane antigen, according to Palette. Educational activities are expected to begin in April, and the agreement could also be extended, according to Palette.
Pylarify was approved by the U.S. Food and Drug Administration in May 2021.
